IGC Pharma (IGC) Stock Statistics & Valuation Metrics

IGC Pharma has a market cap or net worth of $25.75M. The enterprise value is $45.93M.

IGC Pharma has 83,891,590 shares outstanding. The number of shares has decreased by -2.65% in one year.

IGC Pharma’s return on equity (ROE) is -1.78 and return on invested capital (ROIC) is -127.48%.

The current PE Ratio of IGC Pharma is -2.15. IGC Pharma’s PEG ratio is -0.20.

In the last 12 months, IGC Pharma had revenue of 1.34M and earned -13.00M in profits. Earnings per share was -0.22.

In the last 12 months, operating cash flow was -4.59M and capital expenditures -419.00K, giving a free cash flow of -5.01M billion.

IGC Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

IGC Pharma upcoming earnings date is Aug 6, 2025, TBA (Confirmed).

IGC Pharma as a current ratio of 1.58, with Debt / Equity ratio of 0.15%

In the past 12 months, IGC Pharma has paid 0.00 in taxes.

IGC Pharma EV to EBITDA ratio is -2.96, with an EV/FCF ratio of -4.75.

IGC Pharma has $470.00K in cash and marketable securities with $270.00K in debt, giving a net cash position of -$200.00K billion.

Gross margin is 2.58%, with operating margin of -728.48%, and net profit margin of -966.54%.

The average price target for IGC Pharma is $4.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy